Scientific Opinion on the substantiation of a health claim related to olive (Olea europaea L.) leaf water extract and increase in glucose tolerance pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Abstract

Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to olive (Olea europaea L.) leaf water extract and increase in glucose tolerance. The food that is the subject of the health claim, olive leaf water extract standardised by its content of oleuropein, is sufficiently characterised. The claimed effect, an increase in glucose tolerance, is a beneficial physiological effect as long as serum insulin concentrations are not disproportionately increased. One human intervention study showed an increase in glucose tolerance without disproportionate increase in insulin concentrations after daily consumption of the olive leaf water extract for 12 weeks under the conditions of use proposed by the applicant. However, the results have not been replicated in other studies, and no evidence has been provided in relation to the mechanism by which the olive leaf water extract could exert the claimed effect. The scientific evidence is insufficient to establish a cause and effect relationship between the consumption of olive leaf water extract and an increase in glucose tolerance. To avoid confusion, the original version has been removed from the EFSA Journal, but is available on request, as is a version showing all the changes made.Olive leaf water extract and increase in glucose tolerance 2 EFSA Journal 2014;12(5):3655 SUMMARYFollowing an application from Comvita New Zealand Limited, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to olive leaf water extract and increase in glucose tolerance.The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The application includes a request for the protection of proprietary data.The food that is the subject of the health claim is olive (Olea europaea L.) leaf water extract standardised by its content of oleuropein. The Panel considers that the food, an olive leaf water extract (standardised by its content of oleuropein), which is the subject of the health claim, is sufficiently characterised.The claimed effect proposed by the applicant refers to "reduces the glycaemic response following carbohydrate consumption". The target population is adults willing to reduce their glycaemic response. Upon request by EFSA for clarification, the applicant indicated that the claimed effect relates to a long-term increase in glucose tolerance, which could be assessed in vivo in humans by an oral glucose tolerance test (OGTT) following chronic consumption (e.g. 12 weeks) of the food that is the subject of the health claim. The Panel considers that an increase in glucose tolerance is a beneficial physiological effect as long as serum insulin concentrations are not disproportionately increased.The applicant identified two human studies and three animal studies as...

An Optimum Dose of Olive Leaf Extract Improves Insulin Receptor Substrate-1, Tyrosine Kinase, and Glucose Transporters, While High Doses Have Genotoxic and Apoptotic Effects

“…The protective effects of OLE by decreasing the level of oxidative stress-induced DNA damage in peripheral blood cells have been previously demonstrated [33] [34]. In fact, OLE has been recently accepted as a safe product in the category of food additives, approved by the European Food Safety Authority (EFSA) [35]. However, OLE has recently been shown to have cytotoxic, genotoxic, and apoptotic action in an in vitro cell culture medium, depending on dose and time [36] [37] [38].…”

Natural Compounds for Bone Remodeling: A Computational and Experimental Approach Targeting Bone Metabolism-Related Proteins

“…These compounds were further refined based on whether the EFSA had assessed their safety of use in products and their potential beneficial effects on specific functions of the human body. Only 15 compounds have received scientific opinions from the EFSA [42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58], and Table S2 lists the inquiries submitted to the EFSA for the respective phytochemicals along with the corresponding assessments received. Moreover, we explored the possible participation of the 187 natural compounds in clinical trials associated with osteoporosis.…”

Compositional Changes during Storage of Industrially Produced Olive Oils Co-Milled with Olive Leaves

“…Olive leaves represent a cheap and environmentally acceptable source of bioactive compounds [ 11 ] and, therefore, experience increasing interest from pharmaceutical and food companies [ 4 , 16 , 17 ]. Olive leaf extract has strong antioxidant activity, and it is approved by the European Food Safety Agency [ 18 ] as a safe product, which opens up the possibility of its use in the food industry. The use of olive leaves as a raw material in the production of antioxidants could contribute to the efficiency of biological waste disposal, which until now mostly relied on ecologically unacceptable incineration [ 19 ].…”